MRNA241122P50000
- 10.64
- -2.01-15.89%
Moderna Newsroom
Moderna Options Spot-On: On November 18th, 81,993 Contracts Were Traded, With 682.18K Open Interest
Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today
Piper Sandler Reiterates Overweight on Moderna, Lowers Price Target to $69
Stocks Making the Biggest Moves Midday: Moderna, Roku, CVS Health, Robinhood and More
Monday Opens to S&P 500 Climb, Dow Slides as Eyes Look Toward Nvidia | Live Stock
Moderna Stock Climbs as HSBC Upgrades to Buy on Underestimated Pipeline Potential
Today's Pre-Market Movers and Top Ratings | NVDA, TSLA, CVS, LBRT and More
Moderna's Stock Decline After RFK Jr's Appointment Makes an "Attractive Entry Point": Piper Sandler
Moderna Analyst Ratings
Express News | RPT-Buzz-U.S. Stocks Weekly: Dunked
HSBC Upgrades Moderna to Buy From Hold, Adjusts Price Target to $58 From $82
Express News | Moderna : Leerink Partners Cuts Target Price to $31 From $38
Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone
Express News | Moderna : Piper Sandler Cuts Target Price to $69 From $115
Super Micro Plans Filing With Nasdaq Tomorrow. How It Got to the Brink of Delisting
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Trending Stocks This Week as Wall Street Sells off Amid Fed Remarks
The Score: Spirit, Tesla, Moderna and More Stocks That Defined the Week -- WSJ
As RFK Dust Settles, Drug Industry's Response Is Muted -- Barrons.com